| Source: |
| Type: |
| Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors. |
| 482- | CUR, | PDT, | The Antitumor Effect of Curcumin in Urothelial Cancer Cells Is Enhanced by Light Exposure In Vitro |
| - | in-vitro, | Bladder, | RT112 | - | in-vitro, | Bladder, | UMUC3 |
| 480- | CUR, | Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells |
| - | in-vitro, | GBM, | SNB19 |
| 457- | CUR, | Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | BGC-823 |
| 438- | CUR, | Curcumin Reduces Colorectal Cancer Cell Proliferation and Migration and Slows In Vivo Growth of Liver Metastases in Rats |
| - | vitro+vivo, | CRC, | CC531 |
| 456- | CUR, | Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells |
| - | vitro+vivo, | GC, | SGC-7901 |
| 454- | CUR, | Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway |
| - | in-vitro, | GC, | MGC803 |
| 450- | CUR, | Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44 |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT8 |
| 449- | CUR, | Curcumin Suppresses the Colon Cancer Proliferation by Inhibiting Wnt/β-Catenin Pathways via miR-130a |
| - | vitro+vivo, | CRC, | SW480 |
| - | in-vitro, | CRC, | SW480 |
| 442- | CUR, | 5-FU, | Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress |
| - | in-vitro, | CRC, | HCT116 |
| 440- | CUR, | Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells |
| - | vitro+vivo, | CRC, | SW480 | - | vitro+vivo, | CRC, | HT-29 |
| 137- | CUR, | Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling |
| - | in-vitro, | Pca, | DU145 |
| 146- | CUR, | EGCG, | Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 152- | CUR, | Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer |
| - | in-vivo, | Pca, | NA |
| 133- | CUR, | Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 14- | CUR, | Curcumin, a Dietary Component, Has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 Oncogene through the PI3K/mTOR/ETS2 Pathway |
| - | vitro+vivo, | Pca, | PC3 |
| 11- | CUR, | Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway |
| - | in-vitro, | PC, | PANC1 |
| 9- | CUR, | Curcumin Suppresses Malignant Glioma Cells Growth and Induces Apoptosis by Inhibition of SHH/GLI1 Signaling Pathway in Vitro and Vivo |
| - | vitro+vivo, | MG, | U87MG | - | vitro+vivo, | MG, | T98G |
| 165- | CUR, | Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP |
| 181- | CUR, | The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo |
| - | vitro+vivo, | Pca, | DU145 |
| 168- | CUR, | Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism |
| - | in-vitro, | Pca, | PC3 |
| 4826- | CUR, | The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management |
| - | Review, | Var, | NA |
| 4652- | CUR, | Anticancer effect of curcumin on breast cancer and stem cells |
| - | Review, | BC, | NA |
| 4709- | CUR, | Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways |
| - | Review, | Var, | NA |
| 4676- | CUR, | Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway |
| - | vitro+vivo, | Lung, | H460 |
| 2974- | CUR, | Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT15 | - | in-vitro, | CRC, | COLO205 | - | in-vitro, | CRC, | SW-620 | - | in-vivo, | NA, | NA |
| 6234- | CUSP9, | In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma |
| - | Human, | GBM, | NA |
| 6249- | Cyc, | Cyclopamine tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H1299 |
| 6246- | Cyc, | Cyclopamine is a novel Hedgehog signaling inhibitor with significant anti-proliferative, anti-invasive and anti-estrogenic potency in human breast cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 6247- | Cyc, | Sonic Hedgehog Pathway Contributes to Gastric Cancer Cell Growth and Proliferation |
| - | vitro+vivo, | GC, | MKN45 |
| 7443- | CYN, | Cynaropicrin, a sesquiterpene lactone, triggers apoptotic cell death in triple negative breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 7451- | CYN, | Inhibitory effects of cynaropicrin on human melanoma progression by targeting MAPK, NF‐κB, and Nrf‐2 signaling pathways in vitro |
| - | in-vitro, | Melanoma, | A375 |
| 7449- | CYN, | Cytotoxic and pro-apoptotic activities of cynaropicrin, a sesquiterpene lactone, on the viability of leukocyte cancer cell lines |
| - | in-vitro, | lymphoma, | U937 | - | in-vitro, | AML, | Jurkat |
| 1871- | DAP, | Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth |
| - | in-vitro, | AML, | U937 | - | in-vivo, | AML, | NA |
| 6686- | DAP, | Lactoferrin-encapsulated dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer |
| - | in-vivo, | Pca, | NA |
| 6593- | DAS, | Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors |
| 6683- | DCA, | Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts |
| - | Review, | Var, | NA |
| 1865- | DCA, | Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo |
| - | in-vivo, | BC, | NA | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D |
| 1889- | DCA, | A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth |
| - | Review, | Var, | NA |
| 1445- | Deg, | Deguelin--an inhibitor to tumor lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell growth factor-D in lung tumor model |
| - | in-vivo, | lymphoma, | NA | - | in-vitro, | lymphoma, | NA |
| 6676- | Deg, | Deguelin’s Anticancer Bioactivity: Challenges and Opportunities in Medicinal Chemistry |
| - | Review, | Var, | NA |
| 6671- | Deg, | A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy |
| - | in-vitro, | Nor, | BEAS-2B | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 6677- | Deg, | Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis |
| - | in-vitro, | NSCLC, | NA |
| 6706- | DFC, | MET, | Frontiers | Combined Metabolic Targeting With Metformin and the NSAIDs Diflunisal and Diclofenac Induces Apoptosis in Acute Myeloid Leukemia Cells |
| - | in-vitro, | AML, | U937 |
| 6707- | DFC, | Markers of mitochondrial dysfunction during the diclofenac-induced apoptosis in melanoma cell lines |
| - | in-vitro, | Melanoma, | NA |
| 6688- | DFC, | New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells |
| - | in-vivo, | lymphoma, | U937 |
| 6696- | DFC, | MET, | Combined Modulation of Tumor Metabolism by Metformin and Diclofenac in Glioma |
| - | in-vitro, | GBM, | GBM |
| 6695- | DFC, | Inhibition of lactate dehydrogenase A by diclofenac sodium induces apoptosis in HeLa cells through activation of AMPK |
| - | in-vitro, | Cerv, | HeLa |
| 6691- | DFC, | Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway |
| - | in-vitro, | Melanoma, | NA | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HCC1937 | - | in-vitro, | BC, | MCF7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:327 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid